Fig. 5: Recovery of angiogenic defects caused by Med23 knockdown via Ang2 inhibition.

a Cell growth assays to analyze the effects of low (0.1 ng/mL), medium (1 ng/mL), and high (10 ng/mL) doses of a neutralizing Ang2 antibody on the growth of Med23-knockdown HUVECs. n = 3 for each group. The values are the means ± SDs. ***p < 0.001. AA, Ang2 antibody. AAl, low-dose AA; AAm, medium-dose AA; AAh, high-dose AA. b Ang2 neutralization angiogenic assay. Images of the tube-like networks were taken under a ×20 objective lens and on the same scale. The lower panel images were well-fitted from bright-field images (the upper panel) via computer analysis. c Lumen size distribution analysis of the tube formation assays in (b). The result was calculated by fitting the image with NCBI open-source imaging software. d Quantitation of the branch points of the tubes in the Ang2 neutralization angiogenic assays in (b). n = 3 for each group. The values are the means ± SDs. **p < 0.01, ***p < 0.001. e Quantitation of the lumen sizes of the tubes in the Ang2 neutralization angiogenic assays in (b). n = 3 for each group. The values are the means ± SDs. **p < 0.01, ***p < 0.001. f qRT–PCR assays to determine the knockdown efficiency of Ang2 in the control and Med23-knockdown HUVECs. n = 3 for each group. The values are the means ± SDs. **p < 0.01, ***p < 0.001. g Tube formation assays to determine the effect of Ang2 knockdown on angiogenesis in control and Med23-knockdown HUVECs. Scale bar, 200 μm. h Lumen size quantitation of the tubes in the angiogenic assays in (g). n = 3 for each group. The values are the means ± SDs. *p < 0.05, **p < 0.01. i Branch point number quantitation for the tubes in the angiogenic assays in (g). n = 3 for each group. The values are the means ± SDs. **p < 0.01, ***p < 0.001.